Members of the Paediatric Subcommittee of the FDA’s Oncologic Drugs Advisory Committee (pedsODAC) voiced their support for new clinical trials examining promising cancer agents in paediatric patients.
During a 2-day meeting, the panel heard representatives from 5 pharmaceutical companies discuss ongoing or planned early stage paediatric trials.
Read more